DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+13.3%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$118M
AUM Growth
+$118M
(+3.9%)
Cap. Flow
-$3.17M
Cap. Flow
% of AUM
-2.68%
Top 10 Holdings %
Top 10 Hldgs %
44.84%
Holding
84
New
18
Increased
12
Reduced
22
Closed
12
Top Buys
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
$6.77M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$3.99M |
| 3 |
CLLS
Cellectis
CLLS
|
$1.83M |
| 4 |
Rigel Pharmaceuticals
RIGL
|
$1.57M |
| 5 |
BLRX
BioLineRX
BLRX
|
$961K |
Top Sells
| 1 |
Galapagos
GLPG
|
$2.65M |
| 2 |
Cytokinetics
CYTK
|
$2.56M |
| 3 |
DERM
Dermira, Inc.
DERM
|
$2.41M |
| 4 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$2.34M |
| 5 |
TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
|
$2.1M |
Sector Composition
| 1 | Healthcare | 85.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVGR
76
DELISTED
Avinger, Inc. Common Stock
AVGR
| – | – |
0
-25,000
| -100% | -$93K |
|
77
Protagonist Therapeutics
PTGX
$3.62B
| – | – |
-45,586
| Closed | -$1M |
|
78
ESSA Pharma
EPIX
$11.2M
| – | – |
-98,046
| Closed | -$289K |
|
|
79
Cytokinetics
CYTK
$5.98B
| – | – |
-210,306
| Closed | -$2.56M |
|
80
Arbutus Biopharma
ABUS
$753M
| – | – |
-234,000
| Closed | -$573K |
|